A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

• Must be a candidate for standard of care (SOC) treatment of non small cell lungcancer (NSCLC) by concurrent platinum-based doublet chemotherapy with radiationtherapy (cCRT) followed by consolidation durvalumab treatment as determined by theinvestigator and per local guidelines at screening

• Have a medical history of pathologically (histologically or cytologically) provendiagnosis of NSCLC within 3 months prior to enrollment/randomization

• Have locally advanced unresectable stage IIIA or IIIB NSCLC according to the eighthedition lung cancer stage classification

• Have at least 1 target lesion (primary lung lesion or involved lymph node[s]) perRECIST version 1.1 that is amenable to intratumoral and/or intranodal injection andexternal beam radiation therapy (EBRT) as determined by the investigator atscreening

• Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1

Exclusion Criteria:

• Medical history of: (a) Primary immunodeficiency (b) Organ transplant that requirestherapeutic immunosuppression

• Any of the following within 3 months prior to enrollment/randomization: severe orunstable angina, myocardial infarction, major thromboembolic events, clinicallysignificant ventricular arrhythmias or heart failure new york heart associationfunctional classification class III to IV

• Another concurrent or prior primary malignancy (other than NSCLC) within the last 36months at informed consent

• Known allergies, hypersensitivity, or intolerance to any ingredients of JNJ-90301900crystalline solution, platinum-based doublet chemotherapy (ChT), or durvalumab

• Active bleeding diathesis or requirement for therapeutic anticoagulation orantiplatelet that cannot be interrupted or altered for procedures